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Abstract
Pomegranate juice (PJ) is a natural product that inhibits prostate cancer progression. A clinical trial on patients with
recurrent prostate cancer resulted in none of the patients progressing to a metastatic stage during the period of
the trial. We have previously found that, in addition to causing cell death of hormone-refractory prostate cancer cells,
PJ also markedly increases adhesion and decreases migration of the cells that do not die. However, because PJ is a
very complex mixture of components and is found in many different formulations, it is important to identify specific
components that are effective in inhibiting growth and metastasis. Here, we show that the PJ components luteolin,
ellagic acid, and punicic acid together inhibit growth of hormone-dependent and hormone-refractory prostate cancer
cells and inhibit their migration and their chemotaxis toward stromal cell-derived factor 1α (SDF1α), a chemokine
that is important in prostate cancer metastasis to the bone. These components also increase the expression of cell
adhesion genes and decrease expression of genes involved in cell cycle control and cell migration. Furthermore, they
increase several well-known tumor-suppression microRNAs (miRNAs), decrease several oncogenic miRNAs, and
inhibit the chemokines receptor type 4 (CXCR4)/SDF1α chemotaxis axis. Our results suggest that these components
may be more effective in inhibiting prostate cancer growth and metastasis than simply drinking the juice. Chemical
modification of these components could further enhance their bioavailability and efficacy of treatment. Moreover,
because the mechanisms of metastasis are similar for most cancers, these PJ components may also be effective
in the treatment of metastasis of other cancers.
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Introduction
Prostate cancer is the second leading cause of death by cancer among
men in America. It accounts for approximately 30% of all male malig-
nancies; one in six men will be diagnosed with prostate cancer and 1 in
35 will die of the disease [1]. Early stages of localized prostate cancer
can be effectively treated with surgery and radiation, but a majority of
patients develop locally advanced or widespread cancer that requires
hormone ablation therapy. Moreover, 80% to 90% of patients who re-
ceive hormone ablation therapy ultimately develop metastatic castration-
resistant prostate cancer (CRPC) 12 to 33 months after initiation of
hormone ablation therapy [2,3]. Chemotherapy can be used to treat
CRPC, but chemotherapeutic drugs are aggressive and have many side
effects [4,5]. Therefore, there is a major need for more effective and less
toxic therapies to treat prostate cancer.
Sipuleucel-T (Provenge; Dendreon, Seattle, WA), an autologous
cellular immunotherapy, was approved by the Food and Drug Admin-
istration (FDA) in 2010 to treat metastatic prostate cancer. The overall
survival rate of patients who received Sipuleucel-Twas improved, but the
median survival rate was only improved by 4.5 months. In addition, the
effect on time of progression in patients who were asymptomatic or with
limited metastatic disease did not reach statistical significance and treat-
ment is costly [6]. Abiraterone, an inhibitor of androgen biosynthesis,
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has been shown as very promising antiandrogen therapy to prolong over-
all survival rate among patients with metastatic prostate cancer [7].
Moreover, novel androgen receptor antagonist MDV3100, which
blocks androgen from binding to androgen receptor and prevents
nuclear translocation, showed promising antitumor effects in recent
clinical trials [8,9]. Another novel drug, Cabozantinib, a potent dual
inhibitor of the tyrosine kinases met proto-oncogene (MET) and vas-
cular endothelial growth factor receptor 2, has been shown to reduce
or stabilize metastatic bone lesions in CRPC patients [10,11]. However,
all of these treatments have adverse side effects. Recently, there has been
a renewed push to identify natural remedies to fight prostate cancer.
Among the latter is Pomegranate juice (PJ).
Mounting evidence shows that PJ has great potential to inhibit the
growth and reduce the invasiveness of prostate cancer cells both in vitro and
in vivo [12–14]. In a phase II clinical trial, patients with rising prostate-
specific antigen (PSA) were given 8 oz of PJ bymouth daily. PSA doubling
time significantly increased with treatment from a mean of 15 months
at baseline to 54 months post-treatment (P < .001). This statistically
significant prolongation of PSA doubling time and the lack of meta-
static progression in any of the patients strongly suggest a potential
of PJ for treatment of prostate cancer [15]. As a result of these findings,
several studies have shown that PJ affects many of the cellular processes
involved in cell death and also affects signaling pathways that could
inhibit cell migration and invasion [16,17]. We have shown previously
that PJ inhibits the migratory and metastatic properties of hormone
refractory prostate cancer cells by stimulating cell adhesion and inhibit-
ing cell migration/chemotaxis [18]. However, the soluble phase of PJ
contains many components, and as a whole, it is difficult to determine
how to best maximize its use in treating prostate cancer. A way to over-
come this challenge is to identify chemical components of PJ that are
responsible for the antimetastatic effect of the whole juice.
The fruit of PJ can be divided into several anatomic compartments
such as seeds, juice, and peel and all these compartments have been re-
ported to possess antiproliferative and antimetastatic effect against pros-
tate cancer cells [17,19–21]. The juice is a rich source of polyphenolic
compounds including anthocyanins such as delphinidin, cyanidin, and
pelargonidin, which give the fruit and juice its red color. It is also rich in
punicalin, punicalagin, gallagic, quercetin, ferulic acid, caffeic acid, ellagic
acid, and luteolin, which largely account for the antioxidant activity of
the whole fruit [13,22–24]. The seed oil of PJ, which is comprised of
65% to 80% conjugated fatty acids, also contains many compounds
of interest with known anticancer activities. The predominant com-
ponent among these fatty acids is punicic acid [25,26]. However, the
specific components of PJ that have antimetastatic effects against prostate
cancer are largely unknown. There is a short one-and-a-half-page com-
munication reporting that ellagic acid, caffeic acid, luteolin, and punicic
acid inhibit in vitro invasion of human prostate cancer (PC3) cells
across Matrigel (BD Biosciences, San Jose, CA) [27]. Their findings
are interesting but very limited. No studies were presented on the effects
on other processes involved inmetastasis nor was mechanism of action of
these PJ components addressed. Given these findings, we hypothesized
that these specific components of PJ are able to replace the effects of the
full PJ in inhibiting cellular and molecular processes involved in adhe-
sion, migration, and chemotaxis of prostate cancer. Here, we show that
luteolin (L), ellagic acid (E), and punicic acid (P), but not caffeic acid (C),
stimulate molecule cell adhesion, inhibit molecules involved in cell
migration, and inhibit chemotaxis of the cancer cells through CXCR4/
stromal cell-derived factor 1α (SDF1α), a chemokine axis that is very
important in metastasis of prostate cancer cells to the bone. Our
findings strongly suggest that L + E + P can potentially be used to pre-
vent metastasis of prostate cancer.
Materials and Methods
Cell Culture
DU145 and PC3 are hormone-independent prostate cancer epi-
thelial cell lines. LNCaP is an androgen-responsive prostate cancer
epithelial cell line. DU145 and LNCaP prostate cancer epithelial cell lines
were purchased from American Type Culture Collection (Manassas,
VA). PC3 prostate epithelial cell line was a gift from A. Walker (Univer-
sity of California, Riverside). Cells were cultured at 37°Cwith 5%CO2 in
RPMI-1640 supplemented with 10% FBS, penicillin (100 IU/ml), and
streptomycin (100 μg/ml) and used at the times indicated in the results.
Adhesion Assay
PC3, DU145, or LNCaP cells (3 × 105) were plated on gelatin-
coated six-well plates (BD Biosciences, San Jose, CA), allowed to ad-
here, and 24 hours later, treated with PJ and/or PJ components for
12 and/or 24 hours. Cells were then trypsinized, and the time required
to detach all cells was recorded as an indicator of cell adhesiveness.
Migration Assay
Confluent PC3, DU145, or LNCaP cells were wounded using a
rubber scraper to create a scratch, washed, and treated with PJ and/or
PJ components at various concentrations. Cell migration was deter-
mined bymeasuring the distancemigrated by the cells from the wounded
edge to the leading edge of migration at 12, 24, 48, and 72 hours
after treatments were initiated. Scraped cells without treatment were
used as controls.
Chemotaxis Assay
The upper side of 8-μm pore size polycarbonate membranes of
transwells (BD Biosciences) were coated with 50 ng/ml type I col-
lagen (Sigma Chemical Co, St Louis, MO). DU145, PC3, or LNCaP
cells (1 × 105) in 100 μl of culture medium were plated on the upper
side of transwell membranes and were allowed to adhere for 3 hours.
Then, the wells were introduced into 24-well plate and 1000 μl of
RPMI-1640 with 10% FBS medium was added to the lower chamber.
Cells were treated with PJ and/or PJ components for 12 hours. SDF1α
(100 ng/ml) was added to the lower chamber and the cells were
allowed to migrate for 4 hours at 37°C. The cells on the side of the
membrane facing the upper chamber were removed with a cotton
swab, and the membranes were then fixed and stained with 2% tolui-
dine blue in 4% paraformaldehyde. Cells were counted in eight high
power fields per filter to obtain the average number of cells per field.
Total RNA Extraction
DU145 and PC3 cells were treated with PJ components for 12 hours,
and total RNA was extracted using the RNeasy RNA Isolation Kit ac-
cording to the manufacturer’s protocol. Briefly, cells were washed with
ice-cold 1× phosphate-buffered saline (PBS) and lysed on ice with lysis
buffer. Cell lysates were then spun at 12,000 rpm for 5minutes to remove
cell debris, followed by organic extraction to remove proteins. Then,
lysates were loaded into isolation columns and the final RNA product
was dissolved in nuclease-free water. RNA quality was assessed on the
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Figure 1. L + E + C + P inhibits growth, stimulate adhesion, inhibits migration, and inhibits chemotaxis toward SDF1α of hormone-
independent prostate cancer cells. (A) The chemical structure of L, E, P, and C. (B) PC3 cells were treated with four PJ components L +
E + C + P at 4 and 8 μg/ml and counted for increasing times after initiation of treatment. Controls represent no treatment. The medium
containing L + E + C + P was changed daily. (C) PC3 cells were treated with L + E + C + P at 4 and 8 μg/ml, and the percentage of dead
cells was determined by Trypan blue staining at the indicated time points. (D) PC3 cells were plated on gelatin-coated dishes, and 24 hours
later, the medium was changed and the cells were treated with L + E + C + P at 4 and 8 μg/ml. We tested for adhesion to the substrate at
12 and 24 hours after initiation of treatment by recording the time it took for trypsinization to remove all of the cells from the dish. Control
represents no treatment. The reason for not presenting statistical significance is because the loss of adhesion is very similar from culture
to culture and it occurs rapidly when the cells begin to detach. Within each experiment, the times of trypsinization were the same within
1 minute for each specific treatment. (E) PC3 cells were treated with L + E + C + P at 4 and 8 μg/ml for 72 hours and the distance migrated
by the cells from the wounded edge to the leading edge was measured at the indicated time points. Controls represent no treatment. The
medium containing the components was changed daily. (F) PC3 cells were allowed to attach to the top of the filter of the chemotaxis assay
chambers for 4 hours and then treated with L + E+ C+ P at 4 and 8 μg/ml for 12 hours. At this time, 100 ng/ml SDF1αwas introduced into
the lower chamber and the cells found on the bottom of the filter were counted 3.5 hours later. Control had no treatment. The number of
cells found on the underside of the filter was counted 3.5 hours later. Bars represent SEM. ***P < .001; **P < .01; *P < .05.
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Agilent Bioanalyzer 2100 using the Agilent RNA 6000 Nano Assay Kit
(Agilent Technologies, Waldbronn, Germany), and the concentration
was determined using theNanoDropND-1000 spectrophotometer (Na-
noDrop Technologies, Inc, Wilmington, DE).
Affymetrix Microarray and Data Analysis
Affymetrix Human Genome U133 Plus 2.0 Arrays, which contain
more than 54,000 probe sets representing approximately 38,500 genes
and gene sequences, were used. Cells were treated with PJ components
for 12 hours, and total RNA was extracted and evaluated as described
above. Capillary electrophoresis using an Agilent Bioanalyzer 2100 to
confirm the RNA quality levels was used before performing the array
assays. RNA from cells without treatment was used as control. A single
log2 expression measure for each probe set was calculated from image
files (CEL format) using the robust multiarray analysis (RMA) proce-
dure using Agilent GeneSpring GX software. The changes of expression
level between untreated and specific PJ component–treated samples
were compared. Only genes that were overexpressed or underexpressed
by more than two-fold were considered. Once we identified genes of
potential interest, we verified their increase or decrease in expression
by real-time quantitative polymerase chain reaction (qPCR).
Real-Time qPCR
RNA (1 μg) was reverse-transcribed to cDNA by RETROscript
Reverse Transcription Kit (Ambion) at 44°C for 1 hour and 92°C
for 10 minutes. cDNA (2 μl) from the reverse transcription reaction
was added to 23 μl of real-time qPCR mixture containing 12.5 μl of
2× SYBR Green Supermix (Bio-Rad, Hercules, CA) and 200 nM
oligonucleotide primers. PCRs were carried out in a Bio-Rad MyiQ5
Real-Time PCR Detection System (Bio-Rad). The thermal profile was
95°C for 3 minutes followed by 40 amplification cycles, consisting of
denaturation at 95°C for 10 seconds and annealing at 60°C for 30 sec-
onds. Fluorescence was measured and used for quantitative purposes.
At the end of the amplification period, melting curve analysis was done
to confirm the specificity of the amplicon. Fold changes of genes after
treatment with PJ were calculated by the Pfaffl method to normalize
the C t values to the glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) internal control. The following primer sequences were
designed with IDT PrimerQuest (http://www.idtdna.com/Scitools/
Applications/Primerquest/) and used for the reactions:
GAPDH, TCGACAGTCAGCCGCATCTTCTTT and ACCA-
AATCCGTTGACTCCGACCTT;
BCL2, TTTCTCATGGCTGTCCTTCAGGGT and AGGT-
CTGGCTTCATACCACAGGTT;
ROCK2, TTCCAGTGGAGCCAGTTGGAGAAA and TAC-
AAGCCTCACAGTTGGTTGGGA;
EZH2, CAGTTTGTTGGCGGAAGCGTGTAA and AGGA-
TGTGCACAGGCTGTATCCTT;
CDK6, ATTCACTGCCTGGGACACAGTCTT and ACAG-
GCCACTGTGGTAACTCTCAA;
Figure 2. Luteolin, ellagic acid, and punicic acid but not caffeic acid individually inhibit cell migration of hormone-independent PC3 cells.
PC3 cells were treated with individual PJ components (A) luteolin, (B) ellagic acid, (C) punicic acid, and (D) caffeic acid at 4 and 8 μg/ml
for 72 hours, and migration assay was performed as described in Figure 1. Bars represent SEM. ***P < .001; **P < .01; *P < .05.
Translational Oncology Vol. 5, No. 5, 2012 PJ Components and Inhibition of Metastasis Wang et al. 347
DTL, ATTTGGATCTGTGCTGCCTTGCTG and AGGTA-
GCGTTCCACAGCTTTCTGA;
CCNE2, ATGACACCACCGAAGAGCACTGAA and TTG-
GCTAGGGCAATCAATCACAGC;
FSCN1, CAACGATGGCGCCTACAACATCAA and TGGC-
CACCTTGTTATAGTCGCAGA;
CDC25B, TCAGGTGCTGTCCATGGGAAAGAT and
AACTCAACAGACTGGGCTCTTCCA;
TWIST, ACCATCCTCACACCTCTGCATTCT and TTCC-
TTTCAGTGGCTGATTGGCAC;
CCNB1, TGTGGATGCAGAAGATGGAGCTGA and
TTGGTCTGACTGCTTGCTCTTCCT;
PTEN , GGTTGCCACAAAGTGCCTCGTTTA and
AACTGGCAGGTAGAAGGCAACTCT;
CDKN1A, TTAGCAGCGGAACAAGGAGTCAGA and
ACACTAAGCACTTCAGTGCCTCCA.
MicroRNA PCR Array and Data Analysis
MicroRNAs (miRNAs) were extracted from total RNA using RT2
qPCR-Grade miRNA Isolation Kit from SABiosciences (Frederick,
MD). For PCR arrays, miRNA cDNA (100 ng) was amplified
using RT2 miRNA First Strand Kit and RT2 miRNA PCR Array
(MAH-001A) from SABiosciences following the manufacturer’s in-
structions. The fluorescence threshold value (C t) was calculated using
SABiosciences web-based RT2 profiler PCR array data analysis portal
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
siRNA and Vector Transfection
PC3 cells (80–90% confluent) were transfected with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) following the manufacturer’s protocols;
40 nM E-cadherin chimera small-interfering RNA (siRNA) (Abnova,
Taiwan, China) was transfected, and 2 μg/ml pcDNA3.1 HMMR
vector, pcDNA4.1TWISTvector, or pcDNA3CCNE2vector (Addgene
plasmid 19935; Addgene, Cambridge, MA) was transfected. Scratch
wound assay, adhesion assay, and/or cell growth assay were performed
as described above, 24 hours after transfection.
Statistical Analysis
Data analysis was performed using the one-way analysis of variance
on raw data using GraphPad InStat software (GraphPad Software Inc,
La Jolla, CA).
Results
Effect of Luteolin, Ellagic Acid, Punicic Acid, and
Caffeic Acid on Prostate Cancer Cell Growth,
Adhesion, Migration, and Chemotaxis
We treated hormone-independent prostate cancer cells, PC3 and
DU145, with the four PJ components L, E, P, and C (Figure 1A) at
concentrations of both 4 and 8 μg/ml, which are relevant to physiologi-
cal concentration of these components in the juice [27]. We found that
this combination significantly inhibited cell growth of both PC3 (Fig-
ure 1B) and DU145 (Figure W1A). When compared to PJ treatment,
Figure 3. L + E + P is the most potent combination for inhibition of cell migration and chemotaxis toward SDF1α as well as increasing cell
adhesion of hormone-independent prostate cancer cells. PC3 cells were treated with different combination of PJ components L, E, and P at
(A) 4 and (B) 8 μg/ml for up to 72 hours, and migration assay was performed as described in Figure 1. (C) PC3 cells were plated on gelatin-
coated dishes, and 24 hours later, the medium was changed and the cells were treated with PJ components L + E + P at 4 and 8 μg/ml.
Adhesion assay was performed as described in Figure 1. (D) PC3 cells were allowed to attach to the top of the filter of the chemotaxis
chamber for 4 hours and then treated with L + E + P at 4 and 8 μg/ml for 12 hours. Chemotaxis assay was performed as described in
Figure 1. Bars represent SEM. ***P < .001; **P < .01; *P < .05.
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the number of cells floating in the medium after the treatment with the
components was much smaller. Trypan blue staining showed that
the majority of the cells remained viable after treatment with the com-
ponents at either 4 or 8 μg/ml (Figures 1C and W1B). At both 12 and
24 hours, the cells all still looked healthy and no floating cells were seen
in any of the cultures. We also found that the cells strongly adhered
to gelatin-coated substrate, as indicated by increased time to detach all
cells from the culture dish in the presence of treatment with the com-
ponents; by 12 hours of 4 μg/ml L + E + C + P treatment, the cultures
required about double the time to be released by trypsinization (Fig-
ures 1D and W1C ). Moreover, the effect was dose dependent with
8 μg/ml of the combination of PJ components being more potent than
treatment with either 4 μg/ml of the components or 1% PJ. Using the
scratch wound assay, we found that the combination of L + E + C + P
significantly inhibited the migratory capabilities of these cells. We
measured the distance that the cells migrated from the wounded edge
to the migration front and found it to be significantly reduced in the
treated cells beginning as early as 12 hours after treatment, which
continued more than 72 hours, and the effect was dose dependent
(Figures 1E and W1D).
SDF1α is a critical chemokine secreted by bone marrow cells that
attracts prostate cancer cells to the bone. Therefore, we tested whether
the combination of L + E + C + P also inhibits chemotaxis toward
SDF1α. Cells pretreated with L + E + C + P at 4 or 8 μg/ml for 12 hours
before initiation of the chemotaxis assay toward SDF1α showed sig-
nificantly inhibited chemotaxis at both concentrations (Figures 1F and
W1E); at 8 μg/ml, the effects were similar to those of 5% PJ. Therefore,
L + E + C + P has the potential to inhibit metastasis of these cells to the
bone marrow.
Because the combination of L + E + C + P significantly inhibited
processes involved in metastasis, we also tested their effects individually
using the scratch migration assay. L, E, and P each significantly inhibited
cell migration of PC3 and DU145 cells when individually applied at 4
or 8 μg/ml (Figure 2, A–C , and W2, A–C). However, caffeic acid when
applied individually did not show any effects on cell migration of either
cell type (Figures 2D and W2D). On the basis of these findings, we
eliminated caffeic acid as a potential anticancer component and focused
on the effects of the other three components, L, E, and P.
To test whether the combination of L + E + P is more potent than
the combination of any two components, we treated PC3 and DU145
cells with two-component combinations (L + E, L + P, and E + P) and
three-component combination (L + E + P) at 4 or 8 μg/ml (Figures 3,
A and B, and W3, A and B). More than 72 hours of the scratch wound
assay, L + E + P was significantly more potent than any dual combina-
tions at 48 and 72 hours. On the basis of these findings, we performed
the remainder of the studies using L + E + P.
L + E + P significantly increased cell adhesion of PC3 (Figure 3C)
and DU145 (Figure W3C) cells. The detachment time was increased
by 4 or 8 μg/ml of L + E + P treatment for 12 and 24 hours. When
compared to the effect of PJ, L + E + P at 8 μg/ml showed similar effect
to 5% PJ. In addition, chemotaxis toward SDF1α was significantly in-
hibited by pretreatment of PC3 and DU145 cells with L + E + P at 4
or 8 μg/ml (Figures 3D and W3D). The effect of L + E + P at 8 μg/ml
mimicked the effect of 5% PJ. We also tested the effects of L + E + P
combinations at different ratios on cell migration. However, we found
that the ratios of 1:1:1 are the most potent combination.
To determine whether these effects of L + E + P are also found in
androgen-sensitive cells, we used LNCaP, a prostate cancer cell line that
is responsive to androgen, and performed similar studies using growth,
migration, and SDF1α chemotaxis assays. L + E + P at 4 μg/ml signifi-
cantly suppressed cell growth of LNCaP cells (Figure 4A). However,
LNCaP cells are considerably more sensitive to these PJ components
as we observed that cells were largely killed by L + E + P at 8 μg/ml (data
not shown). As a result, we used lower concentrations of L + E + P to
treat LNCaP cells in scratch migration assays and chemotaxis assays. L +
E + P at 2 and 4 μg/ml significantly inhibited cell migration more than
72 hours of treatment (Figure 4B) and chemotaxis toward SDF1α
(Figure 4C). These results suggest that L + E + P are even more effective
in androgen-sensitive than androgen-independent prostate cancer cells.
Figure 4. L + E + P suppresses cell growth, stimulates cell adhe-
sion, and inhibits chemotaxis to SDF1α of LNCaP cell. (A) LNCaP
cells were treatedwith L + E+ P at 4 μg/ml and counted for increas-
ing times after initiation of treatment. (B) LNCaP cells were plated on
gelatin-coated dishes, and 24 hours later, the mediumwas changed
and the cells were treatedwith L + E+ P at 2 and 4 μg/ml. Adhesion
assay was performed as described in Figure 1. (C) LNCaP cells were
allowed to attach to the top of the filter of the chemotaxis chamber
for 4 hours and then treated with L + E + P at 2 and 4 μg/ml for
12 hours. Chemotaxis assaywas performed as described in Figure 1.
Bars represent SEM. ***P < .001; **P < .01; *P < .05.
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Effect of L + E + P on the Expression of Genes Involved in
Cell Growth, Adhesion, Migration, and Chemotaxis
To understand how L + E + P inhibit cell growth, cell migration,
and chemotaxis and increase cell adhesion, we performed Affymetrix
microarray analysis to examine their effects on the expression of genes
involved in these cell functions. For these studies, we used total RNA
from PC3 cells treated with L + E + P at 8 μg/ml for 12 hours and
analyzed for gene expression using Affymetrix Human U133 Plus
2.0 microarrays. PC3 cells were used because these are the most invasive
cells of all of the three types of cells we studied. The data show that L +
E + P inhibit the expression of several important genes involved in cell
growth and cell migration while stimulating the expression of several
genes involved in cell adhesion (Figure 5A, blue arrows and Table 1).
The genes we show that are increased all significantly enhance adhe-
sion or are tumor suppressor genes. Those that are decreased are all
related to stimulation of migration and cytoskeletal components or
extracellular matrix (ECM) molecules that facilitate migration.
To verify the effects of L + E + P on gene expression revealed by the
Affymetrix arrays, we used real-time qPCR to examine mRNA levels
of the following specific genes that are upregulated or downregulated
in the gene arrays: claudin 1 (CLDN1), p21 (CDKN1A), Pten (PTEN),
cyclin E2 (CCNE2), anillin (ANLN), cyclin B1 (CCNB1), denticleless
homolog (DTL), hyaluronan (HA)–mediatedmotility receptor (HMMR),
Twist (TWIST), Rock2 (ROCK2), cell division cycle homolog B
(CDC25B), Bcl2 (BCL2), nexilin (NEXN), cyclin-dependent kinase 6
(CDK6), collagen I (COL1A1), fascin1 (FSCN1), and enhancer of zeste
homolog 2 (EZH2). For the real-time PCR, total RNA was extracted
from PC3 cells treated with L + E + P at 8 μg/ml for 12 hours (Fig-
ure 5B). The mRNA fold change of these genes was highly consistent
with the Affymetrix array results.
Effect of L + E + P on the Level of Cancer-Related miRNAs
miRNAs are naturally occurring small non-coding RNAs that func-
tion as negative regulators of gene expression. They regulate important
cellular functions such as cell proliferation, apoptosis, differentiation,
and development. Mature miRNAs bind to target mRNAs, which
subsequently results in either direct cleavage of the targeted mRNAs
Figure 5. Effect of L + E + P on genes involved in cell growth, cell adhesion, and migration of hormone-independent prostate cancer
cells. (A) Schematic summary of the effects of L + E + P on gene and miRNA expression in hormone-independent prostate cancer cells.
(B) The mRNA levels of CCNE2, ANLN, CCNB1, DTL, HMMR, TWIST, ROCK2, CDC25B, BCL2, NEXN, CDK6, COL1A1, FSCN1, EZH2,
PTEN, CDKN1A, and CLDN1 were determined by using qPCR with RNA extracted from PC3 cells treated with L + E + P at 8 μg/ml
for 12 hours.
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or inhibition of translation. To determine the effects of L + E + P
on cancer-related miRNAs and how they correlate with gene expres-
sion, we used miRNA PCR arrays to analyze the RNA obtained from
PC3 cells treated with L + E + P at 8 μg/ml for 12 hours. Among
88well-known cancer-relatedmiRNAs in the array, we found that those
that function as tumor suppressors are highly increased, whereas those
that function as oncogenic miRNAs are highly decreased (Table 2).
Moreover, we found a consistent correlation between the level of
miRNAs and the expression levels of their predicted target genes as
shown in the Affymetrix mRNA arrays. These correlations are shown
in Figure 5A.
Testing Mechanistically Specific Genes Involved in Cell
Proliferation, Adhesion, and Migration
To determine whether the inhibitory effect of L + E + P on cell pro-
liferation can be reversed, we chose to overexpress cyclin E (CCNE2)
that is the most decreased gene shown in the gene array and is known
to be critical in cell proliferation. We found that the proliferation in-
hibitory effect of L + E + P was significantly reversed by CCNE2 over-
expression (Figure 6A).
We also found that L + E + P significantly increases the protein
levels of E-cadherin (Figure 6B). Loss of this adhesion protein is critical
for invasion of epithelial tumor cells. To determine whether the effect
of L + E + P on cell adhesion can be reversed, we used siRNA to in-
hibit E-cadherin and performed adhesion assays 36 hours after PC3
cells were transfected with E-cadherin siRNA. We found that L + E +
P treatment significantly increases attachment of the untransfected (con-
trol) cells and that the effect is partially reversed by E-cadherin siRNA
(Figure 6C). These results indicate that the effects of L + E + P on cell
adhesion are mediated significantly by increased E-cadherin.
To determine whether the inhibitory effects of L + E + P on cell
migration can be reversed, we chose to overexpress HMMR (a gene
that is known to promote cell migration and was highly decreased
in the gene array) and TWIST (a gene that is known to play a role in
epithelial-to-mesenchymal transitions (EMTs) and was also decreased
in the gene array). The inhibitory effects of L + E + P on cell migration
are partially reversed by overexpression of HMMR or TWIST. Scratch
wounds on PC3 cell cultures were made 24 hours after transfection of
HMMR or TWIST and the migrated distances were measured 36 or
48 hours later. We found that L + E + P treatment significantly de-
creased cell migration of untransfected cells, but the effect was partially
reversed by overexpressing HMMR (Figure 6D) and TWIST (Fig-
ure 6E ). These results indicate that the effects of L + E + P on cell
migration are significantly mediated through decreasing HMMR and/
or TWIST.
Effect of L + E + P on CXCR4/SDF1α Signaling in
Prostate Cancer Cells
Approximately 80% of patients who have died of advanced hormone
refractory prostate cancer have clinical evidence of bone metastases
and 100% have histologic bone involvement [28]. Constitutive pro-
duction of SDF1α by bone marrow stromal cells is a major source of
this chemokine. We show here that L + E + P inhibits chemotaxis of
hormone-independent prostate cancer cells toward SDF1α (Figures 3D
and W3D). Moreover, we found that L + E + P significantly decreased
the protein levels of CXCR4, the receptor for SDF1α that is present
on the prostate cancer cells, by 50% in PC3 cells (Figure 7A) and that
they inhibit the downstream signaling pathway of CXCR4/SDF1α.
We found that L + E + P inhibits activation of PI3K (Figure 7B) and
abolishes phosphorylation/activation of AKT induced by SDF1α (Fig-
ure 7C). These findings show that L +E + P inhibits theCXCR4/SDF1α
chemotaxis axis both at the receptor level and the downstream signaling
pathways, making these components strong contenders for treatment of
prostate cancer metastasis.
Discussion
The studies presented here identify L, E, and P as potential anti-
metastatic components in PJ. We delineate cellular and molecular
mechanisms involved in inhibition of processes critical for metastasis
of prostate cancer cells and show that L + E + P 1) suppresses the
growth of two prostate cancer cell lines that are irresponsive to andro-
gen deprivation and one line that is responsive to androgen deprivation,
Table 1. Gene Analysis of the Effects of L + E + P on PC3 Cells.
Gene Name Product Fold Change Function
CDKN2B Cyclin-dependent kinase inhibitor 2B; p15 ↑4.9 Cell cycle control
CLDN1 Claudin 1 ↑3.6 Adhesion
CDKN2A Cyclin-dependent kinase inhibitor 2A; p16 ↑2.2 Cell cycle control
CDKN1A Cyclin-dependent kinase inhibitor 1A; p21 ↑2 Cell cycle control
PTEN Pten ↑1.6 Tumor suppressor
CCNE2 Cyclin E2 ↓18 Cell cycle control
ANLN Anillin ↓16 Migration
HMMR HA-mediated motility receptor ↓8 Migration
DTL Denticleless homolog ↓7 Cell cycle control
CCNB1 Cyclin B1 ↓5.1 Cell cycle control
CCNB2 Cyclin B2 ↓4.5 Cell cycle control
ROCK2 Rock2 ↓4 Migration
ZEB1 Zinc finger E-box binding homeobox 1 ↓3 EMT
TWIST Twist ↓2.6 EMT
CDC25B Cell division cycle 25 homolog B ↓2.5 Cell cycle control
EZH2 Enhancer of zeste homolog 2 ↓2.3 Oncogenic
NEXN Nexilin ↓2.3 Migration
BCL2 Bcl2 ↓2 Antiapoptotic
COL1A1 Collagen 1 ↓2 Migration
CDK6 Cyclin-dependent kinase 6 ↓1.8 Cell cycle control
FSCN1 Fascin 1 ↓1.7 Migration
L + E + P changes the expression profile of genes involved in the cell growth, cytoskeleton, and cell
adhesion machinery. RNA was extracted from PC3 cells that had been treated with L + E + P at
8 μg/ml for 12 hours, and Affymetrix array analysis was performed as described in Materials and
Methods. Relative mRNA levels are presented as fold change compared with untreated controls.
Table 2. Effect of L + E + P on Cancer-Related miRNAs.
miRNA Function Fold Change Targets
miR144 Tumor-suppressive ↑772941-fold Notch-1
miR-133b Tumor-suppressive ↑177812-fold c-MET, FSCN1
miR-1 Tumor-suppressive ↑66913-fold Cyclin D2, CXCR4, SDF1α
miR-122 Proapoptotic ↑9741-fold Cyclin B1
miR-34c Tumor-suppressive ↑6700-fold E2F3, Bcl2, c-MET
miR-200c Tumor-suppressive ↑5077-fold ZEB1, ZEB2, FN1, MSN
miR-127 Tumor-suppressive ↑4067-fold E2F3, Notch-1, Bcl2
miR-335 Tumor-suppressive ↑3983-fold COLA1, SOX4, TNC
miR-124 Tumor-suppressive ↑1389-fold ROCK2, EZH2, CDK6
miR-181a Tumor-suppressive ↑962-fold K-ras, Bcl2
miR-7 Tumor-suppressive ↑849-fold Bcl2, EGFR, IGF1R
miR-215 Tumor-suppressive ↑820-fold DTL
miR-15a Tumor-suppressive ↑786-fold Fgf2, cyclin E2
Let-7d Tumor-suppressive ↑4-fold Twist
miR-20a Oncogenic ↓13587-fold APP
miR-21 Oncogenic ↓1260-fold TMP1, Pdcd4, MARCKS
miR-9 Oncogenic ↓173-fold E-cadherin
miR-29b Oncogenic ↓48-fold PTEN
miR-181b Oncogenic ↓39-fold PTEN, TIMP3
Effects of PJ on the levels of metastasis-related miRNAs. RNA from PC3 cells treated with L + E + P
at 8 μg/ml for 12 hours was submitted to miRNA PCR array analysis. Relative miRNA levels are
shown as fold change compared with untreated control.
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2) stimulates prostate cancer cells to adhere strongly to the substrate,
3) inhibits the migratory capabilities of prostate cancer cells and their
chemotaxis toward SDF1α, 4) stimulates expression of genes involved
in cell adhesion while reducing expression of genes involved in cell
migration and cell cycle control, and 5) increases the levels of tumor-
suppressive miRNAs while reducing the level of oncogenic miRNAs.
During metastasis, cancer cells lose adhesion to each other and
become migratory. E-cadherin has been shown as a critical adhesion
molecule holding epithelial cells together and preventing them from
breaking away. We found that the protein levels of E-cadherin are
increased, whereas the expression levels of Zeb1 (ZEB1), a zinc finger
transcription repressor of E-cadherin, is inhibited by L + E + P. Fur-
thermore, when the cells are treated with siRNA for E-cadherin, we
observe that the effect of the PJ components is reversed, strongly sug-
gesting that E-cadherin is a key target of L + E + P. Moreover, the
expression of a tight junction protein claudin 1 is increased by treatment
with these components. Therefore, L + E + P increase cell adhesion
through up-regulation of these cell adhesion proteins.
Several molecules involved in cell migration are downregulated by
L + E + P. For example, HMMR binds HA, a molecule that facili-
tates cell migration. Binding of HA to HMMR stimulates the RhoA-
activated protein kinase (ROCK) signal transduction pathway, leading
to tumor cell migration and invasion in various cancers [29]. We found
that the expression ofHMMR and ROCK2 were downregulated by L +
Figure 6. Mechanistic study of the effect of L + E + P on cell growth, cell adhesion, and migration of hormone-independent prostate
cancer cells. (A) PC3 cells were transfected with pcDNA3 CCNE2 vector (2 μg/ml) and treated with L + E + P at 8 μg/ml 24 hours after
transfection. Cell number was counted at a 48-hour time point. (B) Immunoblot analysis for E-cadherin with protein extracts from PC3
cells treated with L + E + P at 8 μg/ml for 24 hours. (C) PC3 cells were transfected with 40 nM E-cadherin siRNA. Twenty-four hours
after transfection, cells were treated with L + E + P at 8 μg/ml for 12 hours and adhesion assay was performed. PC3 cells were trans-
fected with 2 μg/ml (D) pcDNA3.1 HMMR vector or (E) pcDNA4.1 TWIST vector and treated with L + E + P at 8 μg/ml 24 hours after
transfection. Migrated distance was determined at a 48-hour time point. Bars represent SEM. **P < .01; *P < .05.
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E + P. Other proteins such fascin, which is an actin-bundling protein,
that regulates the actin cytoskeleton and the formation of migration
initiating filopodia and actin-binding proteins anillin and nexillin, which
are involved in the regulation of the structure of the cytoskeleton [30,31],
are downregulated by L + E + P. Twist (TWIST) is a basic helix-loop-
helix transcription factor that has been implicated in EMT characterized
by loss of cell adhesion and increased cell motility [32,33]. Therefore,
our results strongly suggest that L + E + P decrease cell migration
through down-regulation of genes involved in cell migration and tran-
scriptional factors involved in EMT.
The three PJ components also inhibit cell division. For example, cyclins
E2 and B1 and cell cycle regulator CDK6 are highly downregulated by
L + E + P treatment. p21, also known as CDK inhibitor 1, binds to and
inhibits the activity of cyclin-CDK complex and therefore functions as a
key regulator to control cell cycle progression [34]. We found that p21
was upregulated by L + E + P treatment. Denticleless homolog (DTL)
is a substrate-specific adaptor of E3 ubiquitin-protein ligase complex
required for cell cycle control. DTL mediates the ubiquitination and
subsequent degradation of p21 [35]. Down-regulation of DTL together
with up-regulation of p21 by L + E + P can potentially lead to suppres-
sion of cell cycle progression. Therefore, L + E + P may inhibit cell
growth through down-regulation of genes involved in cell cycle control.
miRNAs have been shown to have profound impact on post-
transcriptional gene regulation. Aberrant expression of miRNAs occurs
in diverse types of human cancer and in different stages of disease pro-
gression. Our miRNA PCR array results show that many well-known
tumor-suppression miRNAs are highly upregulated, whereas many
oncogenic miRNAs are highly downregulated by L + E + P. Among
the tumor-suppression miRNAs, miR-144 is known to negatively regu-
late the Notch-1 signaling pathway that has been suggested to be in-
volved in a wide variety of human cancers [36]. miR-133b is known to
negatively target receptor tyrosine kinase c-MET and actin-bundling
protein fascin. Aberrantly activated c-MET (also known as hepatocyte
growth factor receptor) has been shown to promote tumor growth,
angiogenesis, and metastasis in various cancers, and fascin is known
as an important regulator of actin cytoskeleton and cell migration
[37,38]. miR-1 is known to negatively target cyclin D2, a protein re-
quired for cell cycle progression, and also CXCR4 and its ligand SDF1α
that are known as important chemotactic proteins in cancer metastasis
[39,40]. miR-212 is known to negatively target antiapoptotic protein
phosphoprotein enriched in diabetes (PED) and transcriptional factor
c-Myc. miR-122 is known to negatively target cyclin B1 [41] and
miR-34c to negatively target transcriptional factor E2F3 and apoptosis
key regulator Bcl2 [42,43]. miR-200c has been shown to inhibit ZEB1
and ZEB2, which are transcriptional repressors of the E-cadherin gene,
whose product is critical in cell adhesion [44]. As a result, L + E + P
might stimulate the expression of E-cadherin by inhibiting its transcrip-
tional repression ZEB1 and ZEB through up-regulating miR-200c.
miR-335 has been identified as a metastasis-suppressive miRNA in
breast cancer by inhibiting type I collagen and tenascin C. Type I col-
lagen is an extracellular matrix molecule involved in cytoskeletal con-
trol, and tenascin C is involved in the regulation of cell migration [45].
miR-124 is known to negatively regulate ROCK2, a kinase involved
in cell migration, and CDK6, a key regulator of cell cycle [46]. Among
the oncogenic miRNAs that are highly downregulated by L + E + P,
miR-21 is one of the first discovered and best-studied oncogenic miRNAs
that negatively regulate several tumor suppressor genes including tropo-
myosin 1 (TMP1) and programmed cell death 4 (PDCD4) protein [47].
miR-9 is known to negatively target E-cadherin [48], and miR-29b and
miR-181b are oncogenic miRNAs known to negatively target tumor
suppressor Pten [49]. Interestingly, the mRNA level of Pten is upregu-
lated by L + E + P treatment that correlates with the down-regulation of
miR-29b and miR-181b. These results show that L + E + P significantly
up-regulate many tumor-suppression miRNAs and significantly down-
regulate many oncogenic miRNAs.
It is also known that, with time, prostate cancer cells develop ways
to bypass the need for testosterone and then the cancer progresses very
rapidly. It has been shown that the CXCR4/SDF1α chemotaxis axis
may play a critical role in the metastasis of prostate cancer to bone
and constitutive production of SDF1α by bone marrow stromal cells
is a major source of this chemokine. We have shown that L + E + P
is capable of inhibiting prostate cancer migration toward SDF1α
as shown in our chemotaxis experiments. In addition, we found that
L + E + P significantly reduced the level of CXCR4 in prostate cancer
cells and inhibited the phosphorylation/activation of AKT. Therefore,
L + E + P may act by suppressing the levels of CXCR4 and inhibiting
the downstream signaling pathway of CXCR4/SDF1α.
Conclusion and Future Prospects
To date, there is no cure for prostate cancer when recurrence occurs
after surgery and/or radiation. In particular, when it recurs after hor-
mone ablation therapy, there are no other effective treatments for
Figure 7. Effect of L + E + P on the SDF1α chemotaxis in prostate
cancer cells. (A) Immunoblot analysis for CXCR4 in extracts pre-
pared from PC3 cells treated with L + E + P at 8 μg/ml for 24 hours.
(B) PI3K immunoblot analysis with protein extract from PC3 cells
treated with 200 ng/ml SDF1α for 8 hours in the presence of L +
E+ P at 8 μg/ml. (C) Phosphor-Akt immunoblot analysis with protein
extract from PC3 cells induced with 200 ng/ml SDF1α for 2 minutes
in the presence of L + E + P at 8 μg/ml.
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deterrence of cancer progression. Here, we show that luteolin, ellagic
acid, and punicic acid, components of PJ, can potentially be used as
antimetastatic treatments to deter prostate cancer metastasis. L + E + P
interfere with multiple biologic processes involved in metastasis of
cancer cells such as suppression of cell growth, increase in cell adhe-
sion, inhibition of cell migration, and inhibition of chemotaxis toward
proteins that are important in prostate cancer metastasis to the bone.
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Supplementary Materials and Methods
Materials
RPMI-1640 medium was acquired from Mediatech (Manassas, VA)
and FBS from Sigma-Aldrich (St Louis, MO). SDF1α was obtained
from ProSpec (Boca Raton, FL) and the RNeasy RNA Isolation Kit
for RNA preparation from Qiagen Inc (Valencia, CA). Secondary
antibody (Ab) was from Thermo Scientific (Rockford, IL). Detection
was done using Supersignal West Dura Kit from Thermo Scientific.
Transfection reagents Lipofectamin 2000 were purchased from Invitro-
gen. All oligonucleotide primers for qPCR were obtained from IDT
(Coralville, IA) and the qPCR iQ SYBR Green Supermix Kit from
Bio-Rad. RT2 qPCR-Grade miRNA Isolation Kit and RT2 miRNA
PCR Array (MAH-001A) were obtained from SABiosciences. pcDNA
3.1 HMMR vector was a gift fromDr E. Turley (University of Western
Ontario). pcDNA4 TWIST vector was a gift from Dr C. Glackin (City
of Hope); pcDNA3 CCNE2 vector (Plasmid 19935) was purchased
from Addgene; E-cadherin siRNA was purchased from Abnova.
CXCR4 Ab was from Abcam (Cambridge, MA); E-cadherin Ab,
phosphor-Akt Ab, and PI3K Ab were from Cell Signaling (Danvers,
MA). PJ was purchased from POMx Wonderful (Los Angeles, CA).
Immunoblot Analysis
DU145 and PC3 cells were treated with PJ components for 12 hours,
washed with ice cold 1× PBS, and lysed on ice with lysis buffer contain-
ing 0.5% Triton X-100, 0.5% NP-40, 10 mM Tris (pH 7.5), 2.5 mM
KCl, 150 mMNaCl, 30 mM β-glycerophosphate, 50 mMNaF, 1 mM
Na3VO4, 0.1% sodium dodecyl sulfate, and additional protease inhib-
itor cocktails (Sigma-Aldrich). Protein concentrations were measured
using the DC Protein Assay Kit (Bio-Rad). Equal amounts of protein
in the cell extracts were mixed with sample buffer, boiled, and analyzed
using 10% acrylamide sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Immunoblot analysis was performed with the HRP-
conjugated secondary Ab (Thermo Scientific), followed by incubation
with West Dura extended duration substrate (Thermo Scientific). Blots
were then reprobed for histone 2A or GAPDH antibody to show equal
loading of proteins.
Figure W1. L + E + C + P inhibits growth, stimulate adhesion, inhibits migration, and inhibits chemotaxis toward SDF1α of hormone-
independent DU145 cells. (A) DU145 cells were treated with four PJ components L + E + C + P at 4 and 8 μg/ml and counted for
increasing times after initiation of treatment. Controls represent no treatment. The medium containing PJ components was changed
daily. Bars represent SEM. ***P < .001; **P < .01. (B) PC3 cells were treated with L + E + C + P at 4 or 8 μg/ml and the percentage of
dead cells was determined by Trypan blue staining at 12, 24, 48, and 72 hours. (C) DU145 cells were plated on gelatin-coated dishes,
and 24 hours later, medium was changed and the cells were treated with PJ components L + E + C + P at 4 and 8 μg/ml. We tested for
adhesion to the substrate at 12 and 24 hours after initiation of treatment by recording the time it took for trypsinization to remove all
of the cells from the dish. Control represents no treatment. Within each experiment, the times of trypsinization were the same within
1 minute for each specific treatment. (D) DU145 cells were treated with PJ components L + E + C + P at 4 and 8 μg/ml for 72 hours, and
the distance migrated by the cells from the wounded edge to the leading edge was measured at the indicated time points. Controls
represent no treatment. The medium containing PJ components were changed daily. (E) DU145 cells were allowed to attach to the top
of the filter of the chemotaxis chamber for 4 hours and then treated with PJ components L + E + C + P at 4 and 8 μg/ml for 12 hours.
At this time, 100 ng/ml SDF1α were introduced into the lower chamber and the cells found on the bottom of the filter were counted
3.5 hours later. Control had no treatment. The number of cells found on the underside of the filter was counted 3.5 hours later. Bars
represent SEM. ***P < .001; **P < .01; *P < .05.
Figure W2. Luteolin, ellagic acid, and punicic acid but not caffeic acid individually inhibit cell migration of hormone-independent DU145 cells.
DU145 cells were treated with individual PJ components (A) luteolin, (B) ellagic acid, (C) punicic acid, and (D) caffeic acid at 4 and 8 μg/ml for
72 hours, and migration assay was performed as described in Figure 1. SEM. ***P < .001; **P < .01; *P < .05.
Figure W3. L + E + P is the most potent combination to inhibit cell migration and its effect on cell adhesion and chemotaxis toward
SDF1α of hormone-independent DU145 cells. DU145 cells were treated with different combination of PJ components L, E, and P at
(A) 4 and (B) 8 μg/ml for 72 hours, and migration assay was performed as described in Figure 1. SEM. ***P < .001; **P < .01; *P < .05.
(C) DU145 cells were plated on gelatin-coated dishes, and 24 hours later, the medium was changed and the cells were treated with PJ
components L + E + P at 4 and 8 μg/ml. Adhesion assay was performed as described in Figure 1. (D) DU145 cells were allowed to
attach to the top of the filter of the chemotaxis chamber for 4 hours and then treated with PJ components L + E + P at 4 and 8 μg/ml
for 12 hours. Chemotaxis assay was performed as described in Figure 1. Bars represent SEM. ***P < .001; **P < .01; *P < .05.
